German biotech MorphoSys AG’s expects around ten new antibody program starts this year, as it boosts investments in go-it-alone projects to between €36 million to €41 million ($50 million to $57 million) from €32 million in 2013.
The plan will be expensive, taking the German biotech into the red for the first time since 2004.